Buy Enzalutamide at factory price from the Manufacturer & Supplier
Enzalutamide is a nonsteroidal antiandrogen (NSAA) medication which is utilized in the treatment of prostate cancer. It is indicated for use in conjunction with castration in treating metastatic castration-resistant prostatic cancer (mCRPC) and nonmetastatic castration-resistant prostate cancer. That is used by mouth.
Buy Enzalutamide at factory price from the suppliers
Pharmaceutical ingredients Manufacturer
Aspect effects of enzalutamide, when added to castration, include asthenia, back pain, diarrhoea, arthralgia, and hot whizzes. Rarely, it can cause seizures. It has a high potential for medication interactions. Enzalutamide is an antiandrogen and acts as an antagonist of the androgen receptor, the neurological target of androgens like testosterone and dihydrotestosterone. Within doing so, it stops the effects of these hormones in the prostate gland and elsewhere in the body.
The device of action of enzalutamide is as an Vom männlichen geschlechtshormon Receptor Antagonist, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 2C19 Inducer.
Enzalutamide acts as a selective silent villain of the androgen radio (AR), the biological target of androgens like testo-sterone and dihydrotestosterone (DHT). In contrast to the first-generation NSAA bicalutamide, enzalutamide would not promote translocation of AR to the cell nucleus and in addition, prevents binding of AR to deoxyribonucleic acid solution (DNA) and AR to coactivator proteins. As such, it is described as an AR signalling inhibitor in addition to the antagonist. The drug is described as a "second-generation" NSAA because it has greatly increased efficacy as an antiandrogen relative to so-called "first-generation" NSAAs like flutamide and bicalutamide. The drug has only 2- to 3-fold lower affinity for the AR relative to DHT, the endogenous ligand of the AR in the prostatic gland.
When LNCaP tissue (a prostate cancer mobile line) engineered to express elevated levels of FLADEM?L (as found in patients with advanced prostate cancer) were treated with enzalutamide, the expression of androgen-dependent genes PSA and TMPRSS2 was down-regulated in contrast to bicalutamide where the expression was upregulated. In VCaP cells which over-express the FLADEM?L, enzalutamide induced apoptosis whereas bicalutamide did not. In addition, enzalutamide behaves as an antagonist of the W741C mutant AR in contrast to bicalutamide which reacts as a pure agonist when bound to the W741C mutant.
Enzalutamide is a nonsteroidal antiandrogen used to take care of metastatic castration-resistant prostatic cancer.
Enzalutamide was first described 5 years ago and was introduced for the treatment of prostate cancer this year. It was the first second-generation NSAA to be introduced. The medication is available widely throughout the world.
Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate tumor who may have previously received docetaxel.
Entamtamide (XTANDI) is an oral androgen receptor villain currently given the green light by clinical studies and the FDA (Food and Drug Administration) for the treatment of metastatic castration-resistant prostate cancer after chemotherapy ( That is, patients with prostate tumor who may have cancer or cancer cells still growing after chemotherapy can prolong their survival.
Although antiandrogen therapy is the treatment of choice for patients with metastatic prostate cancer for 70 years, with the specific exploration of the molecular level of the disease, the researchers found that androgen receptors play a role in driving prostate cancer throughout the illness. Crucial role. A new generation of androgen receptor enemies such as abiraterone and enzalutamide approved by the FDA has demonstrated that they can benefit patients with advanced prostate cancer after docetaxel chemotherapy.
Enzalutamide has approximately 5- to 8-fold higher binding affinity for the androgen receptor (AR) compared to bicalutamide. A single study found an IC50 of 21 nM for enzalutamide and 160 nM for bicalutamide at the AR in the LNCaP cell line (7. 6-fold difference), while another found respective IC50 values of 36 nM and 164 nM (4. 4-fold difference). In accordance, enzalutamide, at a dosage of one hundred sixty mg/day, has been found to produce similar increases in testosterone, estradiol, and luteinizing hormone (LH) levels relative to high-dosage bicalutamide (300 mg/day), and an almost two-fold higher increase in testosterone levels comparative to 150 mg/day bicalutamide (114% versus 66%). These findings suggest that enzalutamide is a significantly more potent and effective antiandrogen in comparison. Also, unlike with the first-generation NSAAs (flutamide, nilutamide, and bicalutamide), there has been no proof of hepatotoxicity or raised liver enzymes in association with enzalutamide treatment in clinical trials.
